Find, compare & contact
Tolrestat API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Tolrestat is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Tolrestat or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Tolrestat API 82964-04-3?

Description:
Here you will find a list of producers, manufacturers and distributors of Tolrestat. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Tolrestat 
Synonyms:
 
Cas Number:
82964-04-3 
DrugBank number:
DB02383 
Unique Ingredient Identifier:
0T93LG5NMK

General Description:

Tolrestat, identified by CAS number 82964-04-3, is a notable compound with significant therapeutic applications. Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

Indications:

This drug is primarily indicated for: For the pharmacological control of certain diabetic complications. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Toxicity:

Classification:

Tolrestat belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings, classified under the direct parent group Naphthalenes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Naphthalenes class, specifically within the None subclass.

Categories:

Tolrestat is categorized under the following therapeutic classes: Aldehyde Reductase, antagonists & inhibitors, Aldose Reductase Inhibitors, Alimentary Tract and Metabolism, Drugs Used in Diabetes, Enzyme Inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Tolrestat is a type of Enzyme Replacements/modifiers


Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.

Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.

On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.

Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.

The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.

Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.